Noninferiority of glucose-6-phosphate dehydrogenase deficiency diagnosis by a point-of-care rapid test vs the laboratory fluorescent spot test demonstrated by copper inhibition in normal human red blood cells
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As reported by others and described from our laboratory [30,31], the CSG qualitative test becomes increasingly insensitive to deficiency at G6PD activities above 30% as it is not designed to distinguish 30–80% from >80% individuals.”
In the citing paper
“Other studies have reported the mis-diagnosis of G6PD heterozygous females by the FST and G6PD RDTs with declining test sensitivities, as low as ~70%, with G6PD activities between 30—< 60% in G6PDd heterozygous females [18, 28,29,30] and in an in vitro system of G6PD enzyme inhibition of red blood cells [20].”
From Dynamics of G6PD activity in patients receiving weekly primaquine for therapy of Plasmodium vivax malaria (2021) · cites this paper as [20]
In the citing paper
“The FST and recently introduced, point-of-care, qualitative rapid diagnostic tests (RDTs) can reliably detect G6PD activities of < 30% activity but they have not been fully validated for detecting heterozygous females having ≥ 30% of normal activity and fail to detect G6PDd with increasing G6PD activity[18,19,20].”
From Dynamics of G6PD activity in patients receiving weekly primaquine for therapy of Plasmodium vivax malaria (2021) · cites this paper as [20]
In the citing paper
“Although rapid tests that can be used at point-of-care were recently introduced for the diagnosis of G6PDd [58, 59], they may fail to accurately identify individuals with intermediate deficiency (30–80% normal enzymatic activity, mainly heterozygote females) [19].”
In the citing paper
“Current G6PD qualitative rapid tests only diagnose deficiency under the 30% threshold [13–16] and women with intermediate activity are diagnosed as G6PD normal by these tests.”
From Validation of the quantitative point-of-care CareStart biosensor for assessment of G6PD activity in venous blood (2018) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evidence and Implications of Mortality Associated with Acute Plasmodium vivax Malaria
Baird, J. K. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00074-12 · Cited by 398 · cited 1×
“Although long viewed as a relatively benign infection, reports and studies from endemic areas and in travelers over the past decade reveal an often pernicious and sometime fatal course associated with a diagnosis of vivax malaria.(3,4) This understanding has focused renewed emphasis and interest on longneglected clini…”
BackgroundSelf-citationMcGready, R., Lee, S., Wiladphaingern, J., Ashley, E., Rijken, M., Boel, M., Simpson, J., Paw, M., Pimanpanarak, M., Mu, O., et al. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70339-5 · Cited by 228 · cited 1×
“malaria.(38,39) Further, some patients with relatively common mutations to 2D6 cytochrome P-450 may remain partially or fully susceptible to relapse despite primaquine therapy.”
BackgroundMalaria in pregnancy in the Asia-Pacific region
Rijken, M. J., McGready, R., Boel, M. E., Poespoprodjo, R., Singh, N., Syafruddin, D., Rogerson, S., & Nosten, F. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70315-2 · Cited by 181
Research works printed but not linked: 36
- Gething, 2012, A long neglected world malaria map: Plasmodium vivax endemicity in 2010, PLoS Negl Trop Dis, 6, e1814, 10.1371/journal.pntd.0001814 · DOI · Paper page
- Price, 2007, Vivax malaria: neglected and not benign, Am J Trop Med Hyg, 77, 79, 10.4269/ajtmh.2007.77.79 · DOI · Paper page
- Anstey, 2012, Plasmodium vivax: risk factors and pathogenesis, Adv Parasitol, 80, 151, 10.1016/B978-0-12-397900-1.00003-7 · DOI · Paper page
- von Seidlein, 2013, Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report, Malar J, 12, 112, 10.1186/1475-2875-12-112 · DOI · Paper page
- White, 2011, Determinants of relapse periodicity in Plasmodium vivax malaria, Malar J, 10, 297, 10.1186/1475-2875-10-297 · DOI · Paper page
- Eyles, 1948, The parasitological pattern of relapsing Plasmodium vivax in military patients, J Natl Malar Soc, 7, 23
- Pukrittayakamee, 2000, Therapeutic responses to different antimalarial drugs in vivax malaria, Antimicrob Agents Chemother, 44, 1680, 10.1128/AAC.44.6.1680-1685.2000 · DOI · Paper page
- Sutanto, 2013, Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia, Antimicrob Agents Chemother, 57, 1128, 10.1128/AAC.01879-12 · DOI
- Douglas, 2011, Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics, Clin Infect Dis, 52, 612, 10.1093/cid/ciq249 · DOI · Paper page
- Baird, 2002, Seasonal malaria attack rates in infants and young children in northern Ghana, Am J Trop Med Hyg, 66, 280, 10.4269/ajtmh.2002.66.280 · DOI · Paper page
- Baird, 2012, Diagnosis and treatment of Plasmodium vivax malaria, Adv Parasitol, 80, 203, 10.1016/B978-0-12-397900-1.00004-9 · DOI
- Beutler, 1954, The hemolytic effect of primaquine. III. A study of primaquine-sensitive erythrocytes, J Lab Clin Med, 44, 177
- Beutler, 2007, Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development, Am J Trop Med Hyg, 77, 779, 10.4269/ajtmh.2007.77.779 · DOI · Paper page
- Clark, 2009, Allelic heterogeneity of G6PD deficiency in West Africa and severe malaria susceptibility, Eur J Hum Genet, 17, 1080, 10.1038/ejhg.2009.8 · DOI · Paper page
- Howes, 2012, G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map, PLoS Med, 9, e1001339, 10.1371/journal.pmed.1001339 · DOI · Paper page
- Beutler, 2008, Glucose-6-phosphate dehydrogenase: a historical perspective, Blood, 111, 16, 10.1182/blood-2007-04-077412 · DOI · Paper page
- Beutler, 1966, A series of new screening procedures for pyruvate kinase deficiency, glucose-6-phosphate dehydrogenase deficiency, and glutathione reductase deficiency, Blood, 28, 553, 10.1182/blood.V28.4.553.553 · DOI
- Boulard, 1972, The effect of copper ion on red cell enzyme activities, J Clin Invest, 51, 459, 10.1172/JCI106833 · doi:10.1172/jci106833
- Beutler, 1994, G6PD deficiency, Blood, 84, 3613, 10.1182/blood.V84.11.3613.bloodjournal84113613 · DOI · Paper page
- Filosa, 1996, Somatic cell selection is a major determinant of the blood cell phenotype in heterozygotes for glucose-6-phosphate dehydrogenase mutations causing severe enzyme deficiency, Am J Hum Genet, 59, 887
- Kim, 2011, Performance of the CareStart™ G6PD deficiency screening test, a point-of-care diagnostic for primaquine therapy screening, PLoS One, 6, e28357, 10.1371/journal.pone.0028357 · DOI · Paper page
- da Silva, 2008, Methods for equivalence and noninferiority testing, Biol Blood Marrow Transplant, 15, 120
- Wolf, 1987, Detection of glucose-6-phosphate dehydrogenase deficiency in erythrocytes: a spectrophotometric assay and fluorescent spot test compared with a cytochemical method, Clin Chim Acta, 168, 129, 10.1016/0009-8981(87)90281-6 · doi:10.1016/0009-8981(87)90281-6
- Wong, 2009, Comparison of detection of glucose-6-phosphate dehydrogenase deficiency using fluorescent spot test, enzyme assay, and molecular method for prediction of severe neonatal hyperbilirubinemia, Singapore Med J, 50, 62
- Clyde, 1981, Clinical problems associated with the use of primaquine as a tissue schizontocidal and gametocytocidal drug, Bull World Health Organ, 59, 391
- Salvidio, 1967, Nature of hemolytic crises and the fate of G6PD deficient, drug-damaged erythrocytes in Sardinians, N Engl J Med, 276, 1339, 10.1056/NEJM196706152762402 · doi:10.1056/nejm196706152762402
- Pannacciulli, 1965, The course of experimentally induced hemolytic anemia in a primaquine-sensitive Caucasian: a case study, Blood, 25, 92, 10.1182/blood.V25.1.92.92 · DOI · Paper page
- George, 1967, Primaquine sensitivity in Caucasians: hemolytic reactions induced by primaquine in G6PD deficient subjects, J Lab Clin Med, 70, 80
- Alving, 1960, Mitigation of the haemolytic effect of primaquine and enhancement of its against the exoerythrocytic forms of the Chesson strain of Plasmodium vivax by intermittent regimens of drug administration: a preliminary report, Bull World Health Organ, 22, 621
- Peters, 2009, Glucose-6-phosphate dehydrogenase deficiency and malaria: cytochemical detection of heterozygous G6PD deficiency in women, J Histochem Cytochem, 57, 1003, 10.1369/jhc.2009.953828 · DOI
- Howes, 2013, Spatial distribution of G6PD deficiency variants across malaria-endemic regions, Malar J, 12, 418, 10.1186/1475-2875-12-418 · DOI · Paper page
- Loucharoen, 2009, Positively selected G6PD-Mahidol mutation reduces Plasmodium vivax density in Southeast Asians, Science, 326, 1546, 10.1126/science.1178849 · DOI · Paper page
- Baird, 2004, Primaquine therapy for malaria, Clin Infect Dis, 39, 1336, 10.1086/424663 · DOI · Paper page
- John, 2012, Primaquine radical cure of Plasmodium vivax: a critical review of the literature, Malar J, 11, 280, 10.1186/1475-2875-11-280 · DOI · Paper page
- Durand, 2014, Efficacy of three different regimens of primaquine for the prevention of relapses of Plasmodium vivax in the Amazon Basin of Peru, Am J Trop Med Hyg, 91, 18, 10.4269/ajtmh.13-0053 · doi:10.4269/ajtmh.13-0053
- Bennett, 2013, Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria, N Engl J Med, 369, 1381, 10.1056/NEJMc1301936 · DOI · Paper page
Cited by
Bancone, G., Gornsawun, G., Chu, C. S., Porn, P., Pal, S., Bansil, P., Domingo, G. J., & Nosten, F. (2018) · PLOS ONE · doi:10.1371/journal.pone.0196716 · Cited by 65
Shitaye, G., Gadisa, E., Grignard, L., Shumie, G., Chali, W., Menberu, T., Belachew, M., Tegegn, G., Challi, S., Curry, J., et al. (2018) · Malaria Journal · doi:10.1186/s12936-018-2437-8 · Cited by 20
Satyagraha, A. W., Sadhewa, A., Panggalo, L. V., Subekti, D., Elyazar, I., Soebianto, S., Mahpud, N., Harahap, A. R., & Baird, J. K. (2021) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0009610 · Cited by 12
Self-citationTaylor, W. R. J., Kim, S., Kheng, S., Muth, S., Tor, P., Christophel, E., Mukaka, M., Kerleguer, A., Luzzatto, L., Baird, J. K., et al. (2021) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0009690 · Cited by 9
Self-citation
Metadata
- Authors
- Baird, J. K., Dewi, M., Subekti, D., Elyazar, I., & Satyagraha, A. W.
- Venue
- Translational Research
- Publisher
- Elsevier BV
- Published
- 2015-06
- Volume
- 165
- Issue
- 6
- Pages
- 677-688
- ISSN
- 1931-5244
- Cited by
- 31
- References
- 3
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- Wellcome Trust (B9RJIXO)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.